Investors & Media

Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting

– Interim results show sustained reduction in hereditary angioedema attacks and no new safety signals in patients treated for one year CARLSBAD, Calif. , Nov. 13, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a Phase 2 open-label extension

Read more
You are now leaving to visit